Literature DB >> 2736710

Salivary passage of 5-fluorouracil during continuous infusion.

G Milano1, A Thyss, J Santini, M Frenay, E Francois, M Schneider, F Demard.   

Abstract

Plasmatic and salivary concentrations of 5-FU were investigated in ten patients given 5-day continuous infusions of 5-fluorouracil (5-FU) (1 g/m2/day). Measurable concentrations of salivary 5-FU were scattered ranging from 6 to 100 ng/ml. Between individual 5-FU concentrations in saliva and plasma the coefficient of correlation was low. The theoretically predicted ratios of 5-FU concentrations in saliva over those in plasma, calculated as a function of salivary pH, did not correlate with the observed ratios, the majority of which ranged between 0.1 and 0.5. Noteworthy, 8 of 10 patients exhibited a more or less pronounced increase in 5-FU salivary excretion during 5-day continuous i.v. infusions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736710     DOI: 10.1007/bf00300243

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.

Authors:  G A Caballero; R K Ausman; E J Quebbeman
Journal:  Cancer Treat Rep       Date:  1985-01

2.  Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma.

Authors:  N Christophidis; G Mihaly; F Vajda; W Louis
Journal:  Clin Chem       Date:  1979-01       Impact factor: 8.327

Review 3.  Continuous infusion or bolus injection in cancer chemotherapy.

Authors:  R W Carlson; B I Sikic
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

Review 4.  Continuous infusion chemotherapy: a critical review.

Authors:  N J Vogelzang
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

Review 5.  Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure.

Authors:  W A Ritschel; G A Tompson
Journal:  Methods Find Exp Clin Pharmacol       Date:  1983-10

6.  Salivary excretion of 5-fluorouracil. I. Fluctuation of the saliva/plasma concentration ratio and salivary clearance in beagle dogs following bolus intravenous administration.

Authors:  J Watanabe; Y Hayashi; K Iwamoto; S Ozeki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-03       Impact factor: 1.645

7.  Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.

Authors:  P Seifert; L H Baker; M L Reed; V K Vaitkevicius
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

8.  Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva.

Authors:  L A Celio; G J DiGregorio; E Ruch; J Pace; A J Piraino
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.

Authors:  S B Howell; C E Pfeifle; W E Wung
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

10.  Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.

Authors:  P I Clark; M L Slevin
Journal:  Eur J Surg Oncol       Date:  1985-09       Impact factor: 4.424

View more
  1 in total

1.  Lysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitro.

Authors:  Rosemary A Ndolo; Yepeng Luan; Shaofeng Duan; M Laird Forrest; Jeffrey P Krise
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.